Black Diamond Therapeutics, Inc.·4

Jun 22, 4:06 PM ET

Raman Prakash 4

4 · Black Diamond Therapeutics, Inc. · Filed Jun 22, 2026

Research Summary

AI-generated summary of this filing

Updated

Black Diamond Therapeutics (BDTX) Director Raman Prakash Receives Award

What Happened
Raman Prakash, a non-employee director of Black Diamond Therapeutics (BDTX), was issued 7,907 shares on June 19, 2026 as an award/acquisition under the company's director compensation policy. The filing reports a per-share value of $1.66 (based on the June 18, 2026 closing price), for a total reported value of $13,126. This was an issuance in lieu of cash compensation rather than an open-market purchase or sale.

Key Details

  • Transaction date: 2026-06-19 (reported on Form 4 filed 2026-06-22). Filing appears timely.
  • Transaction type: Award/Grant (code A) — shares issued as director compensation election.
  • Shares issued: 7,907; Price used for valuation: $1.66 per share; Total value: $13,126.
  • Shares owned after transaction: Not disclosed in the filing.
  • Footnotes: (1) Shares issued under the Sixth Amended and Restated Non-Employee Director Compensation Policy; Prakash elected stock in lieu of cash. (2) $1.66 price equals the June 18, 2026 closing market price used for valuation.

Context
Director stock awards are routine compensation and do not necessarily signal a personal market view. This issuance reflects election of equity instead of cash pay under the company’s director compensation plan, not an open-market buy or sale by the director.

Insider Transaction Report

Form 4
Period: 2026-06-19
Transactions
  • Award

    Common Stock

    [F1][F2]
    2026-06-19$1.66/sh+7,907$13,12645,039 total
Footnotes (2)
  • [F1]These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
  • [F2]The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 18, 2026.
Signature
/s/ Brent Hatzis-Schoch, Attorney-in-Fact|2026-06-22

Documents

1 file
  • 4
    form4-06222026_080600.xmlPrimary